On Tuesday, Gilead Sciences, Inc (NASDAQ: GILD) was 0.23% up from the session before settling in for the closing price of $118.21. A 52-week range for GILD has been $84.34 – $121.83.
Healthcare Sector giant saw their annual sales slid by -38.13% over the last five years. When this article was written, the company’s average yearly earnings per share was at 74.89%. With a float of $1.24 billion, this company’s outstanding shares have now reached $1.24 billion.
The firm has a total of 17600 workers. Let’s measure their productivity.
Gilead Sciences, Inc (GILD) Breakdown of a Key Holders of the stock
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Gilead Sciences, Inc stocks. The insider ownership of Gilead Sciences, Inc is 0.20%, while institutional ownership is 88.23%. The most recent insider transaction that took place on Sep 29 ’25, was worth 1,116,564. In this transaction Chairman & CEO of this company sold 10,000 shares at a rate of $111.66, taking the stock ownership to the 591,203 shares. Before that another transaction happened on Sep 29 ’25, when Company’s Officer proposed sale 10,000 for $111.66, making the entire transaction worth $1,116,564.
Gilead Sciences, Inc (GILD) Recent Fiscal highlights
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 2.02 earnings per share (EPS) during the time that was better than consensus figure (set at 1.55) by 0.47. Wall Street market experts anticipate that the next fiscal year will bring earnings of 2.07 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 74.89% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 26.75% during the next five years compared to -38.13% drop over the previous five years of trading.
Gilead Sciences, Inc (NASDAQ: GILD) Trading Performance Indicators
You can see what Gilead Sciences, Inc (GILD) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.15. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.10. Likewise, its price to free cash flow for the trailing twelve months is 15.69.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 5.03, a number that is poised to hit 2.15 in the next quarter and is forecasted to reach 8.63 in one year’s time.
